Industry Experts

Gregory Opiteck is Vice President and Head of Translational Medicine at Janux Therapeutics, where he leads translational science, biomarkers, clinical pharmacology, and model-informed drug development strategies across the company's oncology and immunology pipeline. With more than 25 years of experience spanning chemistry, translational medicine, and clinical development, he has helped advance dozens of therapeutic programs from research through clinical proof-of-concept. At Janux, Gregory focuses on integrating biomarker, PK/PD, and clinical data to improve development decisions, optimize study design, and accelerate the advancement of innovative cancer therapies for patients.